Review Article
Prognostic and Clinical Value of the Systemic Immune-Inflammation Index in Biliary Tract Cancer: A Meta-Analysis
Table 1
Baseline characteristics of included studies.
| Author
Year | Country | Period | Histology | Patients () | Age (y) median (range) | Sex (M/F) | TNM stage | Cut-off value | Cut-off selection | Treatment | Follow-up (m) | Survival analysis | NOS score |
| | Hu et al. 2019 [15] | China | 2012-2017 | eCCA | 113 | | 75/38 | NA | 456 | ROC | PTBS+125I | NA | OS | 7 | | Zhang et al. 2020 [24] | China | 2013-2017 | iCCA | 128 | | 70/58 | I-III | 1027 | ROC | Surgery | NA | OS, RFS | 7 | | Tsilimigras et al. 2020 [16] | Multi-institution | 2000-2007 | iCCA | 688 | 57 (49-60) | 416/272 | NA | 1150 | ROC | Surgery | 22.3 (10.9-44.6) | OS, CSS | 8 | | Sun et al. 2020 [20] | China | 2003-2017 | GBC | 142 | | 60/82 | I-IV | 600 | Harrell miscellaneous | Surgery | NA | OS | 8 | | Li et al. 2020 [22] | China | 2009-2017 | iCCA | 265 | 57.9 | 134/131 | I-III | 450 | ROC | Surgery | 18 (1-115.4) | OS, RFS | 8 | | Li et al. 2021 [21] | China | 2002-2019 | GBC | 691 | (32-80) | 270/421 | NA | 510 | R package survMisc | Surgery | 53.8 (3 m-18 y) | OS | 8 | | Zhang et al. 2021 [23] | China | 1993-2015 | cHCC-CCA | 220 | 59 (30-81) | 162/58 | I-IV | 331 | ROC | Surgery/+TACE | 22.1 (1-118) | OS, RFS | 8 | | Ren et al. 2021 [19] | China | 2013-2018 | iCCA | 28 | 51.5 (46.8-60) | 25/3 | NA | 447.48 | ROC | TACE/ablation/chemotherapy/+LT | 33.5 | OS | 7 | | Chen et al. 2021 [18] | China | 2012-2020 | GBC | 93 | 62 (32-90) | 62/31 | I-III | 824 | ROC | Surgery | 14 (2-60) | OS | 8 | | Terasaki et al. 2021 [17] | Japan | 2002-2015 | eCCA | 140 | NA | 109/31 | NA | 1450 | Log-rank test and K–M curve | Surgery | 48.2 | OS | 7 |
|
|
NA: not available; OS: overall survival; DFS: disease-free survival; NOS: Newcastle-Ottawa scale; ROC: receiver operating characteristics curve; SII: systemic immune-inflammation index; TNM: tumor node metastasis; GBC: gallbladder cancer; iCCA: intrahepatic cholangiocarcinoma; eCCA: extrahepatic cholangiocarcinoma; cHCC-CCA: combined hepatocellular-cholangiocarcinoma; PTBS: percutaneous transhepatic biliary stenting; TACE: transarterial chemoembolization; LT: liver transplantation.
|
